HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 276, Issue 19, 16064-16069, May 11, 2001

This Article Full Text Full Text (PDF) All Versions of this Article: 276/19/16064    most recent M101224200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kasparkova, J. Articles by Brabec, V. Search for Related Content PubMed PubMed Citation Articles by Kasparkova, J. Articles by Brabec, V. Social Bookmarking                      What's this?

Different Recognition of DNA Modified by Antitumor Cisplatin and Its Clinically Ineffective trans Isomer by Tumor Suppressor Protein p53^*

Jana Kasparkova^§, Sarka Pospisilova^¶, and Viktor Brabec^§

From the  Institute of Biophysics, Academy of Sciences of the Czech Republic, CZ-61265 Brno, Czech Republic and the ^¶ Masaryk Memorial Cancer Institute, CZ-65653 Brno, Czech Republic

The p53 gene encodes a nuclear phosphoprotein that is biologically activated in response to genotoxic stresses including treatment with anticancer platinum drugs. The DNA binding activity of p53 protein is crucial for its tumor suppressor function. DNA interactions of active wild-type human p53 protein with DNA fragments and oligodeoxyribonucleotide duplexes modified by antitumor cisplatin and its clinically ineffective trans isomer (transplatin) were investigated by using a gel mobility shift assay. It was found that DNA adducts of cisplatin reduced binding affinity of the consensus DNA sequence to p53, whereas transplatin adducts did not. This result was interpreted to mean that the precise steric fit required for the formation and stability of the tetrameric complex of p53 with the consensus sequence cannot be attained, as a consequence of severe conformational perturbations induced in DNA by cisplatin adducts. The results also demonstrate an increase of the binding affinity of p53 to DNA lacking the consensus sequence and modified by cisplatin but not by transplatin. In addition, only major 1,2-GG intrastrand cross-links of cisplatin are responsible for this enhanced binding affinity of p53. The data base on structures of various DNA adducts of cisplatin and transplatin reveals distinctive structural features of 1,2-intrastrand cross-links of cisplatin, suggesting a unique role for this adduct in the binding of p53 to DNA lacking the consensus sequence. The results support the hypothesis that the mechanism of antitumor activity of cisplatin may also be associated with its efficiency to affect the binding affinity of platinated DNA to active p53 protein.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				J. Kasparkova, M. Fojta, N. Farrell, and V. Brabec Differential recognition by the tumor suppressor protein p53 of DNA modified by the novel antitumor trinuclear platinum drug BBR3464 and cisplatin Nucleic Acids Res., October 14, 2004; 32(18): 5546 - 5552. [Abstract] [Full Text] [PDF]

				M. Stros, T. Ozaki, A. Bacikova, H. Kageyama, and A. Nakagawara HMGB1 and HMGB2 Cell-specifically Down-regulate the p53- and p73-dependent Sequence-specific Transactivation from the Human Bax Gene Promoter J. Biol. Chem., February 22, 2002; 277(9): 7157 - 7164. [Abstract] [Full Text] [PDF]

				Y. Jung, Y. Mikata, and S. J. Lippard Kinetic Studies of the TATA-binding Protein Interaction with Cisplatin-modified DNA J. Biol. Chem., November 16, 2001; 276(47): 43589 - 43596. [Abstract] [Full Text] [PDF]